scholarly journals Acinar cell carcinoma in childhood: A case report of a very rare tumor

2020 ◽  
Vol 11 (3) ◽  
pp. 3-8
Author(s):  
Apostolos Pourtsidis ◽  
Smaragda Papachristidou ◽  
Orthodoxos Achilleos ◽  
Darius Mirza ◽  
Marina Servitzoglou ◽  
...  

Abstract Introduction Pancreatic tumors are reported rarely in childhood and represent an extremely rare entity in Pediatric Oncology. One of the least common types of pediatric pancreatic tumor is acinar cell carcinoma (ACC). We aim to present a rare case of ACC and the difficulties we faced during diagnosis and treatment. Patient and Methods An 8-year old girl presented with jaundice. Workup revealed a tumor originating from the head of the pancreas with multiple metastatic lesions in her liver. Evaluation of tumor markers revealed elevated levels of AFP. Pathology report was indicative of acinar cell carcinoma of the pancreas. Results After consulting the EXPeRT group (European Cooperative Study Group for Pediatric Rare Tumors), chemotherapy was initiated. Partial response was observed after the first 4 courses with decrease of AFP levels. While planning her surgery, AFP elevated and a second-line course of chemotherapy was administered. Our patient underwent Whipple’s Duodenopancreatectomy with partial metastasectomy. Although the postoperative period was uneventful, AFP continued to rise even after postoperative chemotherapy was administered. There were signs of metastatic disease progression. Our patient received a third-line regimen with no improvement. She received local radiotherapy and a next-line chemotherapy course. Local relapse and metastatic disease progression placed our patient in palliative care. She passed away nine months after the initial diagnosis. Conclusions Acinar cell carcinoma of the pancreas is a rare type of pediatric cancer with very challenging diagnosis and treatment. Cooperation at the European level and multicenter management of those rare cases is vital for the optimum outcome.

2011 ◽  
Vol 202 (1) ◽  
pp. 23-27 ◽  
Author(s):  
Werner Hartwig ◽  
Maike Denneberg ◽  
Frank Bergmann ◽  
Thilo Hackert ◽  
Ulf Hinz ◽  
...  

2001 ◽  
Vol 45 (1) ◽  
pp. 29 ◽  
Author(s):  
Jong Young Oh ◽  
Kyung Jin Nam ◽  
Jong Cheol Choi ◽  
Suck Bin Suh ◽  
Ki Nam Lee ◽  
...  

Pancreas ◽  
2020 ◽  
Vol 49 (6) ◽  
pp. 781-787
Author(s):  
Yuan Zong ◽  
Changsong Qi ◽  
Zhi Peng ◽  
Lin Shen ◽  
Jun Zhou

2013 ◽  
Vol 38 (5) ◽  
pp. 1115-1119 ◽  
Author(s):  
Hae Jin Kim ◽  
Young Kon Kim ◽  
Kee Taek Jang ◽  
Jae Hoon Lim

2010 ◽  
Vol 43 (12) ◽  
pp. 1264-1269
Author(s):  
Yoshio Matsui ◽  
Kazuhito Yano ◽  
Youichirou Tamura ◽  
Takahisa Kageyama

2012 ◽  
Vol 5 (3) ◽  
pp. 969-971 ◽  
Author(s):  
MANUEL MORALES ◽  
MIGUEL ÁNGEL CABRERA ◽  
MARIA DEL CARMEN MAESO ◽  
NOEMÍ FERRER-LÓPEZ

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16253-e16253
Author(s):  
Vishwajith Sridharan ◽  
Mari Mino-Kenudson ◽  
James M. Cleary ◽  
Osama E. Rahma ◽  
Kimberly Perez ◽  
...  

e16253 Background: Acinar cell carcinoma (ACC) is a very rare tumor of the exocrine pancreas, representing less than 1% of all pancreatic malignancies. The majority of data regarding ACC are limited to small case series. Methods: This is a retrospective study conducted at a large healthcare system from 1996-2019. Patients with pathologically confirmed ACC were included, and demographic data, tumor characteristics, and treatment outcomes were abstracted by chart review. Survival curves were obtained by using the Kaplan-Meier method and compared using the log-rank test. Results: Sixty-six patients with ACC were identified. The median patient age at diagnosis was 64, and 42% presented with metastatic disease. The majority presented with abdominal pain or pancreatitis (69%), and laboratory parameters did not correlate with tumor size, metastatic disease, or survival. Several somatic abnormalities were noted in tumors (BRCA2, TP53, and mismatch-repair genes). In patients with localized disease that underwent resection, the median time to develop metastatic lesions was 13 months. The median overall survival (OS) was 24.7 months from diagnosis, with a survival difference based on metastatic disease at diagnosis (median 15 vs 38 mos). Surgery conferred OS benefit in non-metastatic cases (p = 0.006) but not metastatic cases (p = 0.22), and chemotherapy provided OS benefit in metastatic disease (p < 0.01). Patients with metastatic ACC treated after 2010 utilized more platinum-based agents, and there was a OS benefit to FOLFOX or FOLFIRINOX chemotherapy compared to gemcitabine or capecitabine-based regimens (p = 0.006). Conclusions: Pancreatic ACC patients often present with advanced disease. Surgery confers survival benefit among patients presenting with localized disease. The use of FOLFOX or FOLFIRINOX chemotherapy regimens was associated with improved OS in metastatic patients. These data add to our knowledge in this rare malignancy, and improves understanding about the genomic underpinnings, prognosis and treatment for acinar cancers.


1999 ◽  
Vol 60 (8) ◽  
pp. 2202-2206
Author(s):  
Hirofumi NOGUCHI ◽  
Tadashi HORIMI ◽  
Takahiro OKABAYASHI ◽  
Katsuji NAGANO ◽  
Masahito KOTAKA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document